The DOI matches its Crossref record; 52 of the 56 references it cites were found in a registry or an index.
Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone.
Open accessAbstract
Glucocorticoid-induced bone disease is characterized by decreased bone formation and in situ death of isolated segments of bone (osteonecrosis) suggesting that glucocorticoid excess, the third most common cause of osteoporosis, may affect the birth or death rate of bone cells, thus reducing their numbers. To test this hypothesis, we administered prednisolone to 7-mo-old mice for 27 d and found decreased bone density, serum osteocalcin, and cancellous bone area along with trabecular narrowing. These changes were accompanied by diminished bone formation and turnover, as determined by histomorphometric analysis of tetracycline-labeled vertebrae, and impaired osteoblastogenesis and osteoclastogenesis, as determined by ex vivo bone marrow cell cultures. In addition, the mice exhibited a threefold increase in osteoblast apoptosis in vertebrae and showed apoptosis in 28% of the osteocytes in metaphyseal cortical bone. As in mice, an increase in osteoblast and osteocyte apoptosis was documented in patients with glucocorticoid-induced osteoporosis. Decreased production of osteoclasts explains the reduction in bone turnover, whereas decreased production and apoptosis of osteoblasts would account for the decline in bone formation and trabecular width. Furthermore, accumulation of apoptotic osteocytes may contribute to osteonecrosis. These findings provide evidence that glucocorticoid-induced bone disease arises from changes in the numbers of bone cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A high level of glucocorticoid in smokers alters bone metabolism and decreases bone mass either directly by changing the osteoblast and osteoclast activities or indirectly by altering the gastrointestinal absorption and renal reabsorption of calcium [39–42].”
From The Effect of Tobacco Smoking on Bone Mass: An Overview of Pathophysiologic Mechanisms (2018) · cites this paper as [39]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Glucocorticoids can also inhibit osteoblast differentiation (249 -251), osteoblast attachment to bone matrix (252), and osteoblast production of IGF-I (253).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [251]
In the citing paper
“In mice, BMD loss with prednisolone was associated with decreased osteocalcin and decreased bone formation, with no histological or biochemical evidence for increased bone resorption (251).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [251]
In the citing paper
“bone marrow harvested from mice treated with prednisolone showed reduced osteoclastogenic potential (251).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [251]
In the citing paper
“One important component of glucocorticoid biology that is lacking in most cell culture models is the marked depletion of osteoblast numbers in animals treated with glucocorticoids (251).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [251]
In the citing paper
“Bone marrow harvested from mice treated with prednisolone was shown to have markedly reduced osteoblastogenic capacity (251).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [251]
In the citing paper
“The prednisolonerelated increase in bone volume in rats, confirmed in a study described immediately below (262), is not consistent with histological data from patients with glucocorticoid-induced osteoporosis (194) and is a recognized limitation of the model (251).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [251]
In the citing paper
“Glucocorticoids decrease BMD in rats (262, 263), mice (251), and minipigs (264).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [251]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,344
Self-citationBone Histomorphometry : Standardization of Nomenclature, Symbols, and Units
PARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · Cited by 3,258
Self-citationThe Fire of Life: An Introduction to Animal Energetics
Kleiber, M. (1975) · Medical Entomology and Zoology · Cited by 2,529
PARFITT, A. M., Mathews, C. H. E., Villanueva, A. R., Kleerekoper, M., Frame, B., & Rao, D. S. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111096 · Cited by 1,542
Self-citationIncreased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6
Jilka, R. L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C., Abrams, J. S., Boyce, B. F., Broxmeyer, H. E., & Manolagas, S. C. (1992) · Science · doi:10.1126/science.1621100 · Cited by 1,440
Self-citationIdiopathic bone necrosis of the femoral head. Early diagnosis and treatment
Ficat, R. P. (1985) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.67b1.3155745 · Cited by 1,339
Parfitt, A. M. (1994) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240550303 · Cited by 1,001
Self-citationNontraumatic Necrosis of Bone (Osteonecrosis)
Desforges, J. F., & Mankin, H. J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205283262206 · Cited by 965
Cushing, H. (1964) · Journal of neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 849
Osteoblast Programmed Cell Death (Apoptosis): Modulation by Growth Factors and Cytokines
Jilka, R. L., Weinstein, R. S., Bellido, T., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.5.793 · Cited by 578 · cited 3×
“In addition, TUNEL has been used with DNA fragmentation and immunohistochemical studies to demonstrate apoptosis of osteoblastic cells and osteoblasts both in vitro and in vivo (8, 20).”
BackgroundMethodSelf-citation
Research works printed but not linked: 3
- [11]11. Cope, C.L. 1972. The synthetic analogues. In Adrenal Steroids and Dis- ease. Lippincott, Philadelphia, PA. 488-491.
- [17]17. Owen, M. 1985. Lineage of osteogenic cells and their relationship to the stromal system. In Bone and Mineral Research. Volume 3. W.A. Peck, editor. Elsevier, Amsterdam. 1-25.
- [42]42. Manolagas, S.C., R.L. Jilka, T. Bellido, C.A. O'Brien, and A.M. Parfitt. 1996. Interleukin-6-type cytokines and their receptors. In Principles of Bone Bi- ology. J.P. Bilezikian, L.G. Raisz, and G.A. Rodan, editors. Academic Press, San Diego, CA. 701-713.
Cited by
Sorted by citations
Items 201–300 of 999
Prevention of glucocorticoid‐induced bone loss in mice by inhibition of RANKL
Hofbauer, L. C., Zeitz, U., Schoppet, M., Skalicky, M., Schüler, C., Stolina, M., Kostenuik, P. J., & Erben, R. G. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24445 · Cited by 132
Tang, S., Xie, H., Yuan, L., Luo, X., Huang, J., Cui, R., Zhou, H., Wu, X., & Liao, E.-Y. (2006) · Peptides · doi:10.1016/j.peptides.2006.10.005 · Cited by 130
Glucocorticoids Induce Osteocyte Apoptosis by Blocking Focal Adhesion Kinase-mediated Survival
Plotkin, L. I., Manolagas, S. C., & Bellido, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611435200 · Cited by 136
Self-citationLeptin Induces Apoptosis via ERK/cPLA2/Cytochrome c Pathway in Human Bone Marrow Stromal Cells
Kim, G. S., Hong, J. S., Kim, S. W., Koh, J., An, C. S., Choi, J., & Cheng, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m204598200 · Cited by 132
Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis
Migliorini, F., Colarossi, G., Eschweiler, J., Oliva, F., Driessen, A., & Maffulli, N. (2022) · British Medical Bulletin · doi:10.1093/bmb/ldac017 · Cited by 130
“This progressive bone impairment is then exacerbated by a quantitative reduction of osteoblasts.(11) Several pharmacological treatments have been proposed for corticosteroids-induced osteoporosis (CIO).”
Xie, X.-H., Wang, X., Yang, H., Zhao, D., & Qin, L. (2015) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2014.12.002 · Cited by 130
“Takano-Murakami et al [18] also recently found that methylprednisolone (MPSL) sodium succinate inhibited bone formation by suppressing osteoblasts proliferation and bone resorption by suppressing the recruitment of osteoclasts precursors [19].”
Yao, W., Cheng, Z., Pham, A., Busse, C., Zimmermann, E. A., Ritchie, R. O., & Lane, N. E. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23954 · Cited by 128
“Using this model, we have consistently observed trabecular bone loss associated with rapid increases in osteoclast activation and function after 7 days of glucocorticoid excess (19,23,37).”
MethodShi, Y., Oury, F., Yadav, V. K., Wess, J., Liu, X. S., Guo, X. E., Murshed, M., & Karsenty, G. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.01.005 · Cited by 126
“Importantly, we did not observe any increase in osteoblast apoptosis in M3R / bones (Figure 1H), a feature usually observed when bone formation is hampered by corticosterone (Weinstein et al., 1998).”
BackgroundChristopher, M. J., & Link, D. C. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080612 · Cited by 127
“ticoid treatment and estrogen withdrawal suppress osteoblast number through the induction of apoptosis.((22,26))”
BackgroundEijken, M., Koedam, M., van Driel, M., Buurman, C. J., Pols, H. A. P., & van Leeuwen, J. P. T. M. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.11.034 · Cited by 127
Use of Oral Corticosteroids and Risk of Fractures
van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. C. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2005.20.8.1486 · Cited by 168
The Glucocorticoid Receptor: Isoforms, Functions, and Contribution to Glucocorticoid Sensitivity
Lockett, J., Inder, W. J., & Clifton, V. L. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae008 · Cited by 135
Graeff, C., Marín, F., Petto, H., Kayser, O., Reisinger, A., Peña, J. A., Zysset, P. K., & Glüer, C. (2012) · Bone · doi:10.1016/j.bone.2012.10.036 · Cited by 128
Glucocorticoid Signaling and Bone Biology
Komori, T. (2016) · Hormone and Metabolic Research · doi:10.1055/s-0042-110571 · Cited by 131
Glucocorticoid Signaling in Health and Disease: Insights From Tissue-Specific GR Knockout Mice
Whirledge, S., & DeFranco, D. B. (2017) · Endocrinology · doi:10.1210/en.2017-00728 · Cited by 123
“However, paradoxical observations in vitro and in vivo indicate that both cell types are sensitive to glucocorticoid-mediated apoptosis (85).”
BackgroundInfluence of Glucocorticoids on Human Osteoclast Generation and Activity
Sivagurunathan, S., Muir, M. M., Brennan‐Speranza, T. C., Seale, J. P., & Mason, R. S. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041233 · Cited by 125
Glucocorticoid-Induced Osteoporosis: Summary of a Workshop
CANALIS, E. M., & Giustina, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8066 · Cited by 132
Irisin Prevents Disuse-Induced Osteocyte Apoptosis
Storlino, G., Colaianni, G., Sanesi, L., Lippo, L., Brunetti, G., Errede, M., Colucci, S. C., Passeri, G., & Grano, M. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3944 · Cited by 125
“ment and sex steroid deficiency have been shown to increase osteocyte apoptosis in animals and humans.((2,3)) Moreover, the osteocyte death observed in the murine model of estrogen deficiency, temporally and spatially coupled to increased bone resorption, has been shown to resemble that observed in a murine model of d…”
Sher, L. B., Woitge, H. W., Adams, D. J., Gronowicz, G., Krozowski, Z. S., Harrison, J. R., & Kream, B. E. (2003) · Endocrinology · doi:10.1210/en.2003-0655 · Cited by 124
“Reduced proliferation and function of osteoblasts, as well as enhanced osteoblast apoptosis, contribute to the bone loss (5, 6).”
BackgroundLangdahl, B. L., Marín, F., Shane, E. J., Dobnig, H., Zanchetta, J., Maricic, M. J., Krohn, K., See, K., & Warner, M. R. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0917-y · Cited by 126
“However, the loss of bone mass and bone quality in response to glucocorticoids is due primarily to decreased bone formation [3, 5].”
BackgroundMarchetti, M. C., Marco, B. D., Cifone, M. G., Migliorati, G., & Riccardi, C. (2002) · Blood · doi:10.1182/blood-2002-06-1779 · Cited by 124
Fracture non-union: Who is at risk?
Çopuroğlu, C., Calori, G. M., & Giannoudis, P. V. (2013) · Injury · doi:10.1016/j.injury.2013.08.003 · Cited by 124
“costeroids (lead to osteoblast and osteocyte apoptosis and inhibition of osteoblastogenesis) [24,25], chemo-”
Sasaki, N., Kusano, E., Ando, Y., Yano, K., Tsuda, E., & Asano, Y. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.3.479 · Cited by 123
Death of osteocytes turns off the inhibition of osteoclasts and triggers local bone resorption
Gu, G., Mulari, M., Peng, Z., Hentunen, T. A., & Väänänen, H. K. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.06.211 · Cited by 123
Maurel, D. B., Jähn, K., & Lara-Castillo, N. (2017) · Biomedicines · doi:10.3390/biomedicines5040062 · Cited by 127
“While the first exert positive effects on tissue function [82], the latter are known to negatively affect the musculoskeletal unit [83,84].”
BackgroundLv, Y., Yang, Y., Sui, B., Hu, C., Zhao, P., Liao, L., Chen, J., Zhang, L., Yang, T.-T., Zhang, S., et al. (2018) · Theranostics · doi:10.7150/thno.23620 · Cited by 123
“Although we did not show general effects of RESV directly on senescence levels of MSCs and senescence-associated phenotypes of impaired cell viability and self-renew [98], misdirected differentiation toward adipocytes [99], or DNA damage [100] and altered secretion [101], the current findings, particularly on RESV imp…”
Bone disease in patients with long-term renal transplantation and normal renal function
Carlini, R. G., Rojas, E., Weisinger, J. R., López, M., Martinis, R., Arminio, A., & Bellorín-Font, E. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.8289 · Cited by 123
Glucocorticoid-induced osteoporosis in children: impact of the underlying disease
Leonard, M. B. (2007) · PEDIATRICS · doi:10.1542/peds.2006-2023j · Cited by 123
Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy
Söderpalm, A., Magnusson, P., Åhlander, A., Karlsson, J., Kroksmark, A., Tulinius, M., & Swolin‐Eide, D. (2007) · Neuromuscular Disorders · doi:10.1016/j.nmd.2007.05.008 · Cited by 121
From Malthus to motive: How the HPA axis engineers the phenotype, yoking needs to wants
Pecoraro, N. C., Dallman, M. F., Warne, J. P., Ginsberg, A. B., Laugero, K. D., la Fleur, S. E., Houshyar, H., Gómez-Oliver, F., Bhargava, A., & Akana, S. F. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.07.004 · Cited by 125
Chang, J., Li, C.-J., Liao, H.-J., Wang, C., Wang, G., & Ho, M. (2009) · Toxicology · doi:10.1016/j.tox.2009.01.016 · Cited by 120
Is Wnt signalling the final common pathway leading to bone formation?
Milat, F., & Ng, K. W. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.06.002 · Cited by 123
Almeida, M., Martín-Millán, M., Ambrogini, E., Bradsher, R., Han, L., Chen, X.-D., Roberson, P., Weinstein, R., O'Brien, C. A., Jilka, R., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.091017 · Cited by 126
“BMD, vertebral dimensions, osteoblast number, and osteoblast apoptosis were obtained as described previously.((7,30,31)) ERa / and corresponding wildtype (WT) littermate control mice were generated by crossing heterozygous ERaþ/ mice.”
MethodSelf-citationJähn, K., Lara-Castillo, N., Brotto, L. S., Mo, C., Johnson, M., Brotto, M., & Bonewald, L. F. (2012) · European Cells and Materials · doi:10.22203/ecm.v024a14 · Cited by 117
“…such as prolongation of osteoclast life span resulting in increased bone resorption, in addition to apoptosis of both osteoblasts and osteocytes (Weinstein et al., 1998; Weinstein et al., 2000), and induction of osteocyte autophagy (Jia et al., 2011; Xia et al., 2010a) resulting in a net bone loss.”
BackgroundOsteoporosis after liver transplantation
Compston, J. E. (2003) · Liver Transplantation · doi:10.1053/jlts.2003.50044 · Cited by 115
McLaughlin, F., Mackintosh, J., Hayes, B., McLaren, A., Uings, I., Salmon, P., Humphreys, J., Meldrum, E., & Farrow, S. N. (2002) · Bone · doi:10.1016/s8756-3282(02)00737-8 · Cited by 117
Kristo, C., Jemtland, R., Ueland, T., Godang, K., & Bollerslev, J. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02067 · Cited by 118
Prevalence and risk factors of osteoporosis in female SLE patients--extended report
Almehed, K., Forsblad‐d’Elia, H., Kvist, G., Ohlsson, C., & Carlsten, H. (2007) · Lara D. Veeken · doi:10.1093/rheumatology/kem105 · Cited by 117
“On the other hand higher doses may decrease BMD by different mechanisms such as reducing bone formation by negative effects on the osteoblasts [ 31 ].”
BackgroundCharacterization of a new experimental model of osteoporosis in rabbits
Castañeda, S., Calvo, E., Largo, R., González, R., de la Piedra, C., Díaz Curiel, M., & Herrero‐Beaumont, G. (2007) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-007-0797-1 · Cited by 116
“Glucocorticoids induce a loss in cortical and trabecular bone [27], increase osteoclastic resorption, and decrease new bone formation [29–30].”
BackgroundZhen, Y.-F., Wang, G., Zhu, L., Tan, S., Zhang, F., Zhou, X., & Wang, X. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24589 · Cited by 116
“These pathways, i.e. glycogen synthase kinase 3 activation (Yun et al., 2009) and others (Weinstein et al., 1998; Manolagas, 2000; O’Brien et al., 2004) might work together, or independently, with the P53-mPTP signaling to induce cell death (Fig.”
BackgroundSmoking and Dental Implants: A Systematic Review and Meta-Analysis
Mustapha, A., Salame, Z., & Chrcanovic, B. R. (2021) · Medicina · doi:10.3390/medicina58010039 · Cited by 120
“As another example, smoking leads to hypercortisolism [25], which changes osteoblast and osteoclast proper function [26,27].”
BackgroundWissing, K. M., Broeders, N., Moreno‐Reyes, R., Gervy, C., Stallenberg, B., & Abramowicz, D. (2004) · Transplantation · doi:10.1097/01.tp.0000149322.70295.a5 · Cited by 118
“They have a direct inhibitory effect on bone formation by impairing function and survival of osteoblasts (14).”
BackgroundGene expression profiling of glucocorticoid-inhibited osteoblasts
Leclerc, N., Luppen, C., Ho, V., Nagpal, S., Hacia, J., Smith, E., & Frenkel, B. (2004) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0330175 · Cited by 115
“…of insulin-like growth factor-I and bone morphogenetic protein-2 (BMP-2), and inhibit the bone-specific transcription factor Runx2 (Chen et al. 1983, Delany et al. 1995a, Linkhart et al. 1996, Lian et al. 1997, Rogatsky et al. 1997, Chang et al. 1998, Weinstein et al. 1998, Luppen et al. 2003b).”
BackgroundWeinstein, R. S., Jilka, R. L., Almeida, M., Roberson, P. K., & Manolagas, S. C. (2010) · Endocrinology · doi:10.1210/en.2009-1488 · Cited by 115
“To confirm previously observed differences between the placebo control group and either the prednisone alone or PTH alone groups (13, 17), two-group comparisons were analyzed using the unpaired Student’s t test.”
BackgroundMethodInfluentialSelf-citationEberhardt, A. W., Yeager-Jones, A., & Blair, H. C. (2001) · Endocrinology · doi:10.1210/endo.142.3.8048 · Cited by 115
Yao, W., Dai, W., Jiang, L., Lay, E. Y.-A., Zhong, Z. A., Ritchie, R. O., Li, X., Ke, H. Z., & Lane, N. E. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3308-6 · Cited by 116
“through autophagy [8–11].”
Grey, A. B., Chen, Q., Callon, K. E., Xu, X., Reid, I. R., & Cornish, J. (2002) · Endocrinology · doi:10.1210/en.2002-220347 · Cited by 114
Magnesium and vitamin C supplementation attenuates steroid-associated osteonecrosis in a rat model
Zheng, L.-Z., Wang, J.-L., Xu, J., Zhang, X.-T., Liu, B.-Y., Huang, L., Zhang, R., Zu, H., He, X. M., Mi, J., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119828 · Cited by 115
“Excess CS treatment could directly increase apoptosis of osteoblasts and osteocytes [12] , decrease the activity and differentiation of osteoblast [13] , impair fat metabolism [14] and angiogenesis that induces ischemia and eventually lead to SAON [15] .”
BackgroundLi, H., Qian, W., Weng, X., Wu, Z.-H., Li, H.-H., Zhuang, Q., Feng, B., & Bian, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037030 · Cited by 117
“It has been reported that GCs could induce apoptosis of osteoblasts and inhibit its proliferation, thus leading to osteoporosis and osteonecrosis [4].”
BackgroundGlucocorticoids Inhibit Developmental Stage-specific Osteoblast Cell Cycle
Smith, E., Redman, R. A., Logg, C. R., Coetzee, G. A., Kasahara, N., & Frenkel, B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001758200 · Cited by 113
Recent advances in physiological calcium homeostasis
Ramasamy, I. (2006) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2006.046 · Cited by 116
“togenesis, and increased osteoblast apoptosis (508).”
Osteoclasts protect bone blood vessels against senescence through the angiogenin/plexin-B2 axis
Liu, X., Chai, Y., Liu, G., Su, W., Guo, Q., Lv, X., Gao, P., Yu, B., Ferbeyre, G., Cao, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22131-1 · Cited by 116
Glucocorticoid-induced Osteoporosis
Whittier, X., & Saag, K. G. (2015) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.08.005 · Cited by 116
Disorders Associated With Acute Rapid and Severe Bone Loss
Epstein, S., Inzerillo, A. M., Caminis, J. N., & Zaidi, M. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.12.2083 · Cited by 110
“Inhibition of its mineralizing and osteoclast-support function has been documented in in vitro studies.((7)) Thus, glucocorticoids have been shown to inhibit the expression of a variety of key osteoblastic genes, including the collagen A1, fibronectin, transforming growth factor (TGF ), insulinlike growth factor-1 (IG…”
BackgroundInhibin A Is an Endocrine Stimulator of Bone Mass and Strength
Perrien, D. S., Akel, N. S., Edwards, P. K., Carver, A. A., Bendre, M. S., Swain, F. L., Skinner, R. A., Hogue, W. R., Nicks, K. M., Pierson, T. M., et al. (2006) · Endocrinology · doi:10.1210/en.2006-0848 · Cited by 111
Mesenchymal Stem Cells and Osteoblast Differentiation
Aubin, J. E., & Triffitt, J. T. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1.50106-2 · Cited by 163
Steroids in neurooncology: actions, indications, side-effects
Roth, P., Wick, W., & Weller, M. (2010) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32833e5a5d · Cited by 115
Kuang, M., Huang, Y. P., Zhao, X., Zhang, R., Ma, J., Wang, D.-C., & Ma, X. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.32262 · Cited by 112
Bone disease after renal transplantation
Malluche, H. H., Monier‐Faugere, M., & Herberth, J. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.192 · Cited by 110
“and life span (by induction of osteoblast apoptosis)”
Fas/CD95 is associated with glucocorticoid-induced osteocyte apoptosis
Kogianni, G., Mann, V., Ebetino, F. H., NUTTALL, M. E., Nijweide, P. J., Simpson, H., & Noble, B. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.04.048 · Cited by 110
Vertebral osteonecrosis: MR imaging findings and related changes on adjacent levels.
Yu, C., Hsu, C.-Y., Shih, T. T., Chen, B.-B., & Fu, C.-J. (2007) · PubMed Central · Cited by 110
Guo, S., Tao, S., Yin, W., Qi, X., Sheng, J., & Zhang, C. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.16150 · Cited by 110
“Promotion of apoptosis of bone marrow cells is thought to be an important reason for causing ONFH, as it plays a crucial role in destructing the formation of bone tissues [4-10].”
BackgroundCurrent Concepts on the Pathogenesis and Natural History of Steroid-Induced Osteonecrosis
Powell, C., Chang, C. C.-C., & Gershwin, M. E. (2010) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8217-z · Cited by 109
“has shown, in mice models, decreased bone density, serum osteocalcin, and cancellous bone after administration of prednisolone [22].”
BackgroundMolecular mechanisms of immunomodulatory activity of glucocorticoids
Riccardi, C., Bruscoli, S., & Migliorati, G. (2002) · Pharmacological Research · doi:10.1006/phrs.2002.0969 · Cited by 108
The effect of glucocorticoids on bone and muscle
Klein, G. L. (2015) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2015.07.008 · Cited by 108
Langdahl, B. L., Silverman, S. L., Fujiwara, S., Saag, K. G., Napoli, N., Soen, S., Enomoto, H., Melby, T. E., Disch, D. P., Marín, F., et al. (2018) · Bone · doi:10.1016/j.bone.2018.07.013 · Cited by 108
Sfeir, J. G., Drake, M. T., Khosla, S., & Farr, J. N. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.03.011 · Cited by 112
Luppen, C. A., Smith, E., Spevak, L., Boskey, A. L., & Frenkel, B. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.7.1186 · Cited by 108
“bition of cell cycle progression,((3,4)) in particular during a defined commitment stage,((5)) induction of apoptosis,((6)) and impairment of osteoblast function through transcriptional and/or post-transcriptional inhibition of collagen,((7)) Cbfa1,((8)) and growth factors, including insulin-like growth factor (IGF)-1…”
BackgroundInfluentialBehaviour of Nitinol in osteoblast-like ROS-17 cell cultures
Kapanen, A. I., Ilvesaro, J. M., Danilov, A., Ryhänen, J., Lehenkari, P. P., & Tuukkanen, J. (2002) · Biomaterials · doi:10.1016/s0142-9612(01)00143-0 · Cited by 108
Medical Management of Brain Tumor Patients
Drappatz, J., Schiff, D., Kesari, S., Norden, A. D., & Wen, P. Y. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.07.015 · Cited by 111
Chandra, A., Lan, S., Zhu, J., Siclari, V. A., & Qin, L. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.447250 · Cited by 107
“The average life span of osteoblasts is short, about 150 and 12 days in human (1) and mouse (2), respectively, and therefore they should be replenished constantly from progenitors.”
BackgroundVertino, A. M., Bula, C. M., Chen, J., Almeida, M., Han, L., Bellido, T., Kousteni, S., Norman, A. W., & Manolagas, S. C. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410720200 · Cited by 105
Self-citationA rapid, high content, in vivo model of glucocorticoid‐induced osteoporosis
Barrett, R., Chappell, C., Quick, M., & Fleming, A. (2006) · Biotechnology Journal · doi:10.1002/biot.200600043 · Cited by 104
“In vivo studies in mice have shown that glucocorticoid treatment causes a decrease in bone formation through the suppression of osteoblastogenesis and increased osteocyte apoptosis as well as an increase in bone resorption through the prolongation of osteoclast survival [9].”
BackgroundMilne, M. L., Quail, J. M., Rosen, C. J., & Baran, D. T. (2001) · Journal of Cellular Biochemistry · doi:10.1002/1097-4644(20010501)81:2 · Cited by 43
Current concepts in pediatric bone disease
Leonard, M. B., & Zemel, B. S. (2002) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(03)00113-5 · Cited by 104
Richards, C. D., Langdon, C. M., Deschamps, P. A., Pennica, D., & Shaughnessy, S. G. (2000) · Cytokine · doi:10.1006/cyto.1999.0635 · Cited by 104
Fracture Risk Associated with Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease
Lee, T. A., & Weiss, K. B. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200307-926oc · Cited by 104
“Changes in bone mineral density associated with chronic exposure to corticosteroids may be due to increased bone resorption at the cellular level, which is impacted by long-term exposure to corticosteroids (22, 23 ).”
BackgroundFracture healing in the elderly: A review
Foulke, B. A., Kendal, A. R., Murray, D. W., & Pandit, H. G. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.07.014 · Cited by 104
Colocalization of Glucocorticoid and Mineralocorticoid Receptors in Human Bone
Beavan, S. R., Horner, A. A., Bord, S., Ireland, D., & Compston, J. E. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.8.1496 · Cited by 104
Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels
Kondo, T., Kitazawa, R., Yamaguchi, A., & Kitazawa, S. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21414 · Cited by 103
Yudoh, K., Matsuno, H., Nakazawa, F., Katayama, R., & Kimura, T. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.8.1453 · Cited by 103
Corticosteroid receptors, macrophages and cardiovascular disease
Rickard, A. J., & Young, M. J. (2009) · Journal of Molecular Endocrinology · doi:10.1677/jme-08-0144 · Cited by 105
Rath, S. N., Strobel, L. A., Arkudas, A., Beier, J. P., Maier, A., Greil, P., Horch, R. E., & Kneser, U. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2012.01545.x · Cited by 101
“In vivo apoptotic OB and osteocytes are demonstrated in patients with glucocorticoidinduced osteoporosis [34].”
BackgroundOsteoporosis Associated with Excess Glucocorticoids
Shaker, J. L., & Lukert, B. P. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.014 · Cited by 100
詫摩, 敦., Kaneda, T., Sato, T., Ninomiya, S., Kumegawa, M., & Hakeda, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300213200 · Cited by 100
SOD3 Reduces Inflammatory Cell Migration by Regulating Adhesion Molecule and Cytokine Expression
Laurila, J. P., Laatikainen, L. E., Castellone, M. D., & Laukkanen, M. O. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005786 · Cited by 101
“Among the most potent drugs are glucocorticoids that downregulate the expression of numerous inflammatory chemokines, cytokines and adhesion molecules [3– 5], which, however, are not entirely without adverse effects such as delayed myocardial tissue healing, osteoporosis, and blood vessel calcification [6–9].”
BackgroundGafni, R. I., & Baron, J. (2007) · PEDIATRICS · doi:10.1542/peds.2006-2023d · Cited by 99
Beneš, H., Weinstein, R. S., Zheng, W., Thaden, J. J., Jilka, R. L., Manolagas, S. C., & Reis, R. J. S. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.4.626 · Cited by 99
“(8–12) Specific mouse strains undergo progressive osteopenia after maturity((13,14)) accompanied by reduced number and func tion of osteoblasts, ((11,12))similar if not identical to senescent bone changes in humans.”
BackgroundSelf-citationChang, J., Li, C.-J., Wu, S., Yeh, C.-H., Chen, C., Fu, Y., Wang, G., & Ho, M. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.047 · Cited by 98
Postmenopausal osteoporosis in rheumatoid arthritis: The estrogen deficiency-immune mechanisms link
Sapir‐Koren, R., & Livshits, G. (2017) · Bone · doi:10.1016/j.bone.2017.06.020 · Cited by 99
Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle
Søe, K., & Delaissé, J. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.113 · Cited by 97
Wan, J. T., Sheeley, D. M., Somerman, M. J., & Lee, J. S. (2020) · Bone Research · doi:10.1038/s41413-020-0088-1 · Cited by 96
11β-Hydroxysteroid Dehydrogenase Type 1 Activity Predicts the Effects of Glucocorticoids on Bone
Cooper, M. S., Blumsohn, A., Goddard, P. E., Bartlett, W. A., Shackleton, C. H. L., Eastell, R., Hewison, M., & Stewart, P. M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-022025 · Cited by 97
Post-transplant hypophosphatemia
Levi, M. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00755.x · Cited by 96
Apelin suppresses apoptosis of human osteoblasts
Xie, H., Yuan, L., Luo, X., Huang, J., Cui, R., Guo, L., Zhou, H., Wu, X., & Liao, E.-Y. (2006) · APOPTOSIS · doi:10.1007/s10495-006-0489-7 · Cited by 96
“Apoptosis may also play an important role in the third most common cause of osteoporosis, glucocorticoid-induced osteoporosis [45, 46].”
BackgroundGlucocorticoids: Complications to Anticipate and Prevent
Gensler, L. S. (2013) · The Neurohospitalist · doi:10.1177/1941874412458678 · Cited by 100
“In a large part, this is due to the GC effects on the osteoblast lineage.(9,10) This is especially interesting in that the treatment of this condition is with agents such as bisphosphonates that prevent bone resorption.”
BackgroundAn Update on Glucocorticoid-Induced Osteoporosis
Lane, N. E. (2001) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70196-4 · Cited by 96
Sarkar, D., Nagaya, T., Koga, K., Nomura, Y., Gruener, R., & Seo, H. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.3.489 · Cited by 95
Apoptotic Osteocytes and the Control of Targeted Bone Resorption
Plotkin, L. I. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0194-3 · Cited by 93
Metadata
- Authors
- Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C.
- Affiliations
- University of Arkansas for Medical Sciences (US)
- Venue
- Journal of Clinical Investigation
- Published
- 1998-07-15
- Volume
- 102
- Issue
- 2
- Pages
- 274-282
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC508885
- OpenAlex
- W2002315967
- Cited by
- 1,753
- References
- 56
- Citations by year
- 2026: 25 · 2025: 35 · 2024: 44 · 2023: 63 · 2022: 55 · 2021: 69 · 2020: 65 · 2019: 60 · 2018: 59 · 2017: 63 · 2016: 72 · 2015: 59 · 2014: 77 · 2013: 70 · 2012: 74
- FWCI
- 15.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health (5r01ar043003-05)
- National Institute on Aging (P01 AG-13918, P01AG013918)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR43003)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- glucocorticoid-induced osteoporosis, osteoblastogenesis, osteoblast apoptosis, osteocyte apoptosis, prednisolone, avascular necrosis, bone formation, bone turnover, osteoclastogenesis, trabecular bone, bone mineral density, osteocalcin
- MeSH terms
- Adult, Animals, Bone and Bones, Bone Marrow Cells, Bone Resorption, Cells, Cultured, Female, Glucocorticoids, Humans, Male, Osteoblasts, Osteocytes, Osteoporosis, Prednisolone, Spine, Bone Density, Apoptosis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
